HIV-1 Peptide Immunogen, Multivalent
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV Infections
Phase 1
A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
CompletedNCT00000846
Target: 36Updated: 2005-06-24
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
CompletedNCT00000795
Target: 28Updated: 2008-09-09